• Aljedani et al. (2024). Functional selection in SH3-mediated activation of the PI3 kinase. bioRxiv.
  • Bratti et al. (2024). INA03: A Potent Transferrin-Competitive Antibody-Drug Conjugate against CD71 for Safer Acute Leukemia Treatment. Mol Cancer Ther 23: 1159-1175.
  • Calbert et al. (2024). 4'-Ethynyl-2'-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress. Mol Cancer Ther 23: 683-699.
  • Cuny et al. (2024). Cinacalcet Reverses Short QT Interval in Familial Hypocalciuric Hypercalcemia Type 1. J Clin Endocrinol Metab 109: 549-556.
  • Desaunay et al. (2023). The Recurrent Liver MAN2A1-FER Oncoprotein Lacks Kinase Activity: Implications for the Use of Tyrosine Kinase Inhibitors. Cell Mol Gastroenterol Hepatol.
  • Garciaz et al. (2024). Venetoclax Resistance in Acute Myeloid Leukemia. Cancers (Basel) 16: 1091.
  • Hoffer et al. (2024). ChemoDOTS: a web server to design chemistry-driven focused libraries. Nucleic Acids Res 52: W461-W468.
  • Lopez et al. (2024). ETx-22, a Novel Nectin-4-Directed Antibody-Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4-Expressing Tumors. Cancer Res Commun 4: 2998-3012.
  • Montserrat-Gomez et al. (2024). PDZome-wide and structural characterization of the PDZ-binding motif of VANGL2. Biochim Biophys Acta Proteins Proteom 1872: 140989.
  • Cuny et al. (2024). Cinacalcet reverses short QT interval in Familial Hypocalciuric Hypercalcemia type 1. J Clin Endocrinol Metab. 109: 549–556. doi: 10.1210/clinem/dgad494
  • Desaunay et al. (2024). The Recurrent Liver MAN2A1-FER Oncoprotein Lacks Kinase Activity: Implications for the Use of Tyrosine Kinase Inhibitors. Cell Mol Gastroenterol Hepatol. 17: 667–669. doi: 10.1016/j.jcmgh.2023.12.007
  • Hoffer et al. (2024). ChemoDOTS: a web server to design chemistry-driven focused libraries. Nucleic Acids Res. 52: W461–W468. doi: 10.1093/nar/gkae326
  • Savary et al. (2023). Fusion-negative rhabdomyosarcoma 3D organoids to predict effective drug combinations. Cell Rep Med. 12: 101339. doi: 10.1016/j.xcrm.2023.101339
  • Ariey-Bonnet et al. (2023). Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergisms. EBioMedicine. 95: 104752. doi: 10.1016/j.ebiom.2023.104752
  • Saez-Ayala et al. (2023). From drug repositioning to structure-based design for acute lymphoblastic leukemia. Nat Commun. 14: 3079. doi: 10.1038/s41467-023-38668-2
  • Carrasco et al. (2022). CRCM5484: A BET-BDII selective compound with differential anti-leukemic drug modulation. J Med Chem. 65: 5660–5674. doi: 10.1021/acs.jmedchem.1c02168
  • Ganier et al. (2022). Small-molecule inhibitors of PTK7/β-Catenin interaction in colorectal cancer. ACS Chem Biol. 17: 1061–1072. doi: 10.1021/acschembio.1c00826
  • Garcia et al. (2021). Fragment-based design targeting syntenin PDZ2 domain. Eur J Med Chem. 223: 113601. doi: 10.1016/j.ejmech.2021.113601
  • Lagresle-Peyrou et al. (2021). RAC2 mutation linked to SCID and bone marrow hypoplasia. Haematologica. 106: 404–411. doi: 10.3324/haematol.2019.230250